As aap gears up for a US launch of LOQTEQ in H2, its FY15 guidance looks attainable. As expected, Q2 trading was soft, reflecting the lumpy orders in Biomaterials. Taking into account the combined effect of €5m lower net cash and rolling forward, we trim our valuation from €3.05 to €2.96/share.
24 Aug 2015
US LOQTEQ launch poised to drive H2 recovery
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
US LOQTEQ launch poised to drive H2 recovery
As aap gears up for a US launch of LOQTEQ in H2, its FY15 guidance looks attainable. As expected, Q2 trading was soft, reflecting the lumpy orders in Biomaterials. Taking into account the combined effect of €5m lower net cash and rolling forward, we trim our valuation from €3.05 to €2.96/share.